TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences^® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer (SITC) 38^th Annual Meeting being held November 1-5, 2023, in San Diego, California.

Presentation details for SITC 2023 are as follows:

Late Breaker Oral Presentation: Clinical Activity of SD-101 with Immune Checkpoint Inhibition (ICI) in Metastatic Uveal Melanoma Liver Metastasis (MUM-LM) from the PERIO-01 Phase 1 Trial
Presenter: Sapan P. Patel, M.D., Director of the Uveal Melanoma Program, The University of Texas MD Anderson Cancer Center
Abstract: 1534
Session: Late-Breaking Abstract Session
Time: Saturday, November 4, 11:25 a.m. PDT
Poster Presentation also available in the Poster Hall and in the Virtual ePoster Hall

Poster Presentation: PERIO-03: Pressure Enabled Intrapancreatic Delivery of SD-101 with Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma – Initial Safety and Feasibility Experience
Abstract: 647
Presenter: Michael S. Lee, M.D., Associate Professor, The University of Texas MD Anderson Cancer Center
Time: Friday, November 3, 9:00 a.m. – 7:00 p.m. PDT

Poster Presentation: Checkpoint Inhibitor Administered Either Systemically of Subcutaneously Enhances the Anti-Tumor Immunity of SD-101 Delivered by Pressure-enabled Drug Delivery (PEDD) Device in Treating Liver Metastasis (LM)
Abstract: 1123
Presenter: Chandra C. Ghosh, Ph.D., TriSalus Life Sciences
Time: Friday, November 3, 9:00 a.m. – 7:00 p.m. PDT

The presentations will be available here following their respective sessions.

About TriSalus Life Sciences

TriSalus Life Sciences^® is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.

The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that SD-101 delivered via PEDD may have favorable immune effects within the liver and systemically. The target for SD-101, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. SD-101 delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on Twitter and LinkedIn.

Forward Looking Statements

Statements made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company’s PEDD drug delivery technology and SD-101 investigational immunotherapy. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company’s PERIO clinical trials, and other risks described in the Company’s filings with the Securities and Exchange Commission under the heading “Risk Factors.” All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231025508206/en/